Different modes of action were proposed to explain the anti-tumor activity of PD-1/PD-L1 blockade combined with mAbs that block latent TGF-β1 activation (9) or neutralize all three TGF-β1, β2 and β3 isoforms (10, 11). This evidence concerns the gene TGFB1 and neoplasm.